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Background: COL11A1 is a large complex gene around 250 kb in length and consisting of 68 exons. Pathogenic
mutations in the gene can result in Stickler syndrome, Marshall syndrome or Fibrochondrogenesis. Many of the
mutations resulting in either Stickler or Marshall syndrome alter splice sites and result in exon skipping, which
because of the exon structure of collagen genes usually leaves the message in-frame. The mutant protein then
exerts a dominant negative effect as it co-assembles with other collagen gene products. To date only one large
deletion of 40 kb in the COL11A1, which was detected by RT-PCR, has been characterized. However, commonly
used screening protocols, utilizing genomic amplification and exon sequencing, are unlikely to detect such large
deletions. Consequently the frequency of this type of mutation is unknown.
Case presentations: We have used Multiplex Ligation-Dependent Probe Amplification (MLPA) in conjunction with
exon amplification and sequencing, to analyze patients with clinical features of Stickler syndrome, and have
detected six novel deletions that were not found by exon sequencing alone.
Conclusion: Exon deletions appear to represent a significant proportion of type 2 Stickler syndrome. This
observation was previously unknown and so diagnostic screening of COL11A1 should include assays capable of
detecting both large and small deletions, in addition to exon sequencing.
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Stickler syndrome (OMIM # 108300, 604841, 184840),
first described in 1965 [1] most commonly occurs as an
autosomal dominantly inherited connective tissue dis-
order. It is caused by mutations in collagen genes that en-
code the heterotypic collagen fibrils present in cartilage
and vitreous, namely COL2A1, COL11A1 and COL11A2
[2-4]. These genes encode different collagen α chains that
co-assemble into either a type II collagen homotrimer (all
three chains being products of the COL2A1 gene), or a
type XI collagen heterotrimer that can contain products
from all three genes [5]. We have recently demonstrated
the use of MLPA to detect large deletions encompassing* Correspondence: ar204@cam.ac.uk
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reproduction in any medium, provided the orthe whole COL2A1 gene [6] but no equivalent system was
available for COL11A1. The COL11A1 gene is approxi-
mately 250 kb in length, located on chromosome 1p21 and
comprises in total 68 exons. To date, the majority of muta-
tions in COL11A1 affect the consensus splice sites of exons
encoding the collagen helical domain, and those that have
been analyzed by RT-PCR have all indicated exon skipping.
Because skipping of these exons leaves the message in-
frame and the Gly-Xaa-Yaa repeating collagen motif in
register, this results in mutant collagen α chains capable of
co-assembly with α chains synthesized from the normal
genes, resulting in a dominant negative effect [6,7]. Only
one large deletion (~40 kb) encompassing exons 32–43 has
previously been described [8]. However, this was identified
by analyzing mRNA via RT-PCR, and so the commonly
used strategy of amplifying relatively small genomic regions
and exon sequencing means that similar mutations couldl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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large deletions is unknown [9]. The aim of this study was
to detect COL11A1 copy number alterations using a multi-
plex ligation-dependent probe amplification (MLPA) assay
[10]. Here we present six examples of Stickler syndrome
which display exon deletions of COL11A1 found by this
technique, that were not detected by exon sequencing alone.
Methods
MLPA
During a 2 year period between mid 2010 and mid 2012,
patient samples, submitted to the Cambridge Regional,
Molecular Genetics Diagnostic Service UK, were tested for
genomic rearrangements in the COL11A1 gene using
MLPA, as previously described [10]. Due to the large num-
ber of exons in COL11A1 and the limitation of the number
of probes which can be included in an MLPA assay, two
different assays (P381 and P382) were developed.
The COL11A1 gene is alternatively spliced and no sin-
gle transcript contains all 68 exons, these have also been
numbered 1–67 [7] with the alternatively spliced exons
6 and 7 being labeled 6A and 6B. The most commonly
used cDNA reference sequence used for reporting muta-
tions is NM_001854.3, which contains all of the 68
exons except exon 7 (also referred to as exon 6B). An al-
ternative transcript NM_080629.2 includes exon 7 but
excludes exon 6 (alternatively referred to as exon 6A).
Here we use the exon numbering of 1–68, and the
cDNA reference sequence NM_001854.3 to describe the
effect on the cDNA and protein, where c.1 refers to the
A of the initiating ATG codon (unless otherwise stated).
The MLPA assays were designed by MRC-Holland
(Amsterdam, the Netherlands) and comprise in total fifty
seven COL11A1 exon specific probes. Twenty two probes
were located at other chromosomal locations and served
as reference probes. The exon specific probes in each
kit are detailed in Figure 1A and also on the manu-
facturer’s web site (www.mrc-holland.com/WebForms/
WebFormMain.aspx). No probes are present for exons
13, 14, 24, 32, 33, 46, 48, 51, 53, 56 and 66 of the COL11A1
gene. Note that the MLPA kits and the cDNA reference
sequence NM_001854.3 names the exons 1–68. Both
MLPA assays contain 9 quality control probes to as-
sess DNA denaturation and DNA quantity, and also
for the X and Y chromosome. MLPA was performed
according to manufacturer’s protocol [www.mrc-holland.
com/WebForms/WebFormMain.aspx]. Fragment ana-
lysis was conducted using GeneMarker software [www.
softgenetics.com; Soft Genetics, State College, PA, USA].
Validation of the two sets of MLPA probes for COL11A1
was established by analyzing DNA from 50 normal controls
as well as two control DNAs from patients with known de-
letions. The positive controls were a deletion of exons 32–
43 [8] that was detected by both sets of probes and a 27 bpdeletion in exon 44 [6] that was detected by only one of the
probe sets. These normal and positive controls showed that
the MLPA assays were performing as expected, data for the
large deletion is shown in Figure 1. The two MLPA probes
sets were then used in addition to routine exon sequencing
when analyzing patients with Stickler syndrome.
Long range PCR was used to determine if certain
exons not covered by the MLPA probe set (due to the
limited number of probes in each assay) were included
or absent from the deleted regions. Patient DNA was
amplified using either Sequalprep [Invitrogen, Life Tech-
nologies Ltd, Paisley PA4 9RF, UK] or a long PCR en-
zyme mix [Thermo Fisher scientific; Hemel Hempstead,
HP2 7GE, UK] along with primers known to be outside
of the deleted area. Typical cycling conditions were 94°C
3 min followed by 10 cycles consisting of 94°C 30 sec,
55°C 30 sec, 68°C 8 min, followed by 25 cycles consisting
of 94°C 30 sec, 55°C 30 sec, 68°C 8 min + 20 sec/cycle.
The elongation time was extended to 14 min when try-
ing to amplify particularly large regions of DNA.
Case presentations
Deletions were detected in six patients in whom no mu-
tation was found by exon sequencing and are illustrated
in Figure 2.
Patient 1
The proband (male) was examined at age 7 months due to
Pierre Robin sequence. The patient was not myopic and
there was no sensorineural hearing loss. However there
was a family history of myopia and retinal detachment.
Examination of the mother showed her to be a low myope,
with a beaded vitreous architecture. One probe set (P382)
detected a deletion of exons 6–43, and the other probe set
(P381) a deletion of exons 8–42, (Figure 2A) resulting in a
minimal deleted region of exons 6–43 [c.781-3276, p.
Tyr261-Pro1092] As exons 5 and 44 are included within
both probe sets no further analysis was performed. In the
alternative transcript NM_080629.2 this deletion would
encompass c.781-3312, p.Lys261-Pro1104.
Patient 2
The proband (female) was seen at age 14 years and was
found to have abnormal vitreous gel architecture, with a
beaded phenotype. She had a flat midface with nasal bridge
hypoplasia, anteverted nares and micrognathia (Figure 3A).
There was both sensorineural and conductive hearing loss
and she used hearing aids with good effect. Radiographs
showed irregularity of end plates of several of the cervical,
thoracic and lumbar vertebrae. There was also some anter-
ior wedging of multiple vertebral bodies. One MLPA probe
set (P381) detected a deletion of exons 15–25, and the
other probe set a deletion of exons 16–23 (P382, Figure 2B).
Because the two sets of probes did not cover exons 13 and
P381  del 34-42 P382  del 35-43
P382
A
B Positive control: del Exons 34-43
P381
Figure 1 Validation of the MLPA probe sets. In addition to 50 normal DNAs the probe sets were used to analyze a positive control with a deletion
of exons 32–43. The top two panels (A) show the difference in peak height between a normal control (red) and the positive control (blue) for both MLPA
kits. The size and target of each product is also indicated. This data is also represented in the bottom two panels (B), where blue squares represent control
amplicons, green squares are probes for COL11A1 that fall within peak ratios of 1.2 -0.8 of a normalised control. Red squares fall above or below peak ratios
of 0.8, indicating a duplicated or deleted region. The probes for the X and Y chromosomes (far left) may differ depending upon the gender of the DNA
control. Probes for COL11A1 exons 32 and 33, which are known to be within the deleted region, are not included in either kit.
Vijzelaar et al. BMC Medical Genetics 2013, 14:48 Page 3 of 6
http://www.biomedcentral.com/1471-2350/14/4814, DNA from this patient was amplified with primers
upstream of exon 12 and downstream of exon 26. The
amplified product was sequenced which demonstrated
that exon 14 was also contained within the deleted region
[c.1486-2142, p.Pro496-Lys714] but that exon 13 was not
deleted. The mutation was also present in her sister
(Figure 3B), her father and grandfather are also thought to
be clinically affected but their DNA has not been analyzed.
Patient 3
The female proband (Figure 3D) was examined at age 29.
She had previously had a left retinal detachment. The right
eye had an abnormal vitreous architecture with a beadedphenotype and a quadrantic lamellar cataract. There was a
family history of retinal detachment on her paternal side.
MLPA analysis (Figure 2E) indicated a deletion of exon 49
[c.3655-3708, p.Gly1219-Asp1236]. As exon 48 is not cov-
ered by the two probe sets, long range PCR and sequen-
cing using primers encompassing exons 48–50 was
performed, which confirmed deletion of exon 49 and that
exon 48 was not included in the deleted region. The muta-
tion was also confirmed in her father (Figure 3C).
Patient 4
A two and a half year old male proband was found to be




P382  del 39
P382  del 49
P381  del 41-42
P382 del 6-43P381  del 8-42
del Exons 6-43
P381  del 15-25 P382  del 16-23
del Exons 15-25
P381  del 50-58 P382  del 49-55
F del Exons 49-58
Figure 2 MLPA Detects Multi Exon Deletions. DNA from the six cases (A-F) were analyzed by MLPA. Blue squares represent control amplicons.
Green squares are probes for COL11A1 that fall within peak ratios of 1.2 -0.8 of a normalised control. Red squares fall above or below peak ratios
of 0.8, indicating a duplicated or deleted region. The probes for the X and Y chromosomes (far left) may differ depending upon the gender of
the DNA control.




Figure 3 Facial Photographs of patients with deletions in the COL11A1 gene. Two sisters (A and B) with a deletion of COL11A1 exons
14–25. A father and daughter (C and D) with a deletion of COL11A1 exon 49.
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drome. No sensorineural hearing loss was demonstrated,
but there was a history of recent glue ear. Examination re-
vealed a beaded vitreous phenotype and a high-arched pal-
ate, but no midline clefting. Deletions of exons 41 and 42
[c.3025-3168, p.Gly1009-Val1056] were detected by MLPA
(Figure 2D), as probes for exons 40 and 43 are included in
the two probe sets no further analysis was required.
Two additional mutations were detected in DNA from
other patients with Stickler syndrome (Figure 2C and F).
These were a deletion of a single exon, 39 [c.2863-2916, p.
Gly955-Gln972] and a deletion of exons 49–58 [c.3655-
4302, p.Gly1219-Met1434]. In this latter case it could not
be confirmed whether or not exon 48 was included in the
deleted region, probably due to the large size of the region
needed to be amplified by long range PCR.
Conclusion
Here we have described the design and utilization of
MLPA probes sets that cover 57 of the 68 exons of the
COL11A1 gene, and have detected six novel deletions in
patients with Stickler syndrome that would have been
overlooked by exon sequencing alone. All six leave the
message in frame and the repeating Gly-Xaa-Yaa amino
acid sequence of the collagen triple helical region in
register and the C-propeptide region, through which
type XI collagen chains assemble into heterotrimers, in-
tact. So these mutant molecules are capable of co-
assembling with normal procollagen and consequently
disrupt their normal function. The six deletions de-
scribed here were not detected by exon sequencing. Dur-
ing the same period that these mutations were detected,twenty two other COL11A1mutations were identified by
exon sequencing in the Cambridge Regional Molecular
Genetics Diagnostic Laboratory, UK. [www.cuh.org.uk/
addenbrookes/services/clinical/genetics/genetics_labs/
contacts.html]. So, although the exact frequency of large
deletions in COL11A1 remains uncertain, they would ap-
pear to represent a significant proportion of type 2 Stickler
syndrome cases, and laboratories offering diagnostic se-
quencing of COL11A1 should include a protocol capable
of detecting deletions of various sizes.
As next generation sequencing becomes a standard
method of mutation detection in diagnostic service labora-
tories, it may be possible to recognize gene deletions by
identifying regions where there is homozygosity and a re-
duction in read depth. This may be more achievable using
capture methods rather than sequencing PCR products,
where identification of large deletions may be dependant
upon primer design. In the short term deletions identified
by next generation sequencing may need to be verified by
another method to confirm the mutation.
Five of the six deletions were confined to the collagen
triple helical region of the molecule. One other also in-
cluded the alternatively spliced exons 6, 7 and 9 which
form part of the variable N-propeptide. However, the indi-
viduals with this region deleted did not appear clinically
different from other patients with type 2 Stickler syn-
drome. This probably reflects that, as with the other
multi-exon and single-exon deletions, the mutant α chains
co-assemble with normal α chains synthesized from the
COL2A1, COL11A1 and COL11A2 genes, forming an ab-
normally folded molecule that undergoes intracellular
retention and degradation [11].
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